Šalis: Pietų Afrika
kalba: anglų
Šaltinis: South African Health Products Regulatory Authority (SAHPRA)
Servier
COVERSYL® 4 mg SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): COVERSYL ® 4 mg COMPOSITION: Each COVERSYL 4 mg tablet contains 4 mg perindopril , terbutylamine salt. PHARMACOLOGICAL CLASSIFICATION: A 7.1.3 Vascular medicines - other hypotensives. PHARMACOLOGICAL ACTION: COVERSYL (perindopril) is a specific, non-sulphydryl competitive angiotensin-1 converting enzyme (ACE) inhibitor. Perindopril acts through its active metabolite, perindoprilat, the other metabolites being pharmacologically inactive. Following oral administration the absorption of perindopril is rapid (peak concentration within 1 hour), and relatively complete (plasma-availability above 75%). The peak concentration of perindoprilat, the active metabolite, is reached within 3 to 4 hours and peak pharmacological activity is obtained within 4 to 6 hours. In terms of trough versus peak blood pressure effect, the trough effect ranges between 75 - 100% of peak effect. Perindopril and perindoprilat both have a low volume of distribution and plasma protein binding is weak. Perindoprilat binds to angiotensin converting enzyme at both plasma and tissue levels. Apart from active perindoprilat, perindopril gives rise to 5 metabolites all of which are inactive. Perindopril is eliminated in the urine and the half-life of its free fraction is approximately one hour. Breakdown of the bond between perindoprilat and the angiotensin converting enzyme leads to a pharmacodynamic half-life of about 25 hours. Elimination of perindoprilat is slower in the elderly, as well as in patients with cardiac failure or renal failure. In such patients dosage adjustments should be applied in relation to the degree of reduction in creatinine clearance. Reduction in blood pressure in patients treated with perindopril was accompanied by a red Perskaitykite visą dokumentą